Addressing Ancestry and Sex Bias in Pharmacogenomics
The association of an individual's genetic makeup with their response to drugs is referred to as pharmacogenomics. By understanding the relationship between genetic variants and drug efficacy or toxicity, we are able to optimize pharmacological therapy according to an individual's genotype. Pharmacogenomics research has historically suffered from bias and underrepresentation of people from certain ancestry groups and of the female sex. These biases can arise from factors such as drugs and indications studied, selection of study participants, and methods used to collect and analyze data. To examine the representation of biogeographical populations in pharmacogenomic data sets, we describe individuals involved in gene-drug response studies from PharmGKB, a leading repository of drug-gene annotations, and showcaseCYP2D6, a gene that metabolizes approximately 25% of all prescribed drugs. We also show how the historical underrepresentation of females in clinical trials has led to significantly more adverse drug reactions in females than in males.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:64 |
|---|---|
| Enthalten in: |
Annual review of pharmacology and toxicology - 64(2024) vom: 23. Jan., Seite 53-64 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Corpas, Manuel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alleles |
|---|
| Anmerkungen: |
Date Completed 24.01.2024 Date Revised 24.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1146/annurev-pharmtox-030823-111731 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359516262 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359516262 | ||
| 003 | DE-627 | ||
| 005 | 20240124231916.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1146/annurev-pharmtox-030823-111731 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1269.xml |
| 035 | |a (DE-627)NLM359516262 | ||
| 035 | |a (NLM)37450899 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Corpas, Manuel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Addressing Ancestry and Sex Bias in Pharmacogenomics |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.01.2024 | ||
| 500 | |a Date Revised 24.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The association of an individual's genetic makeup with their response to drugs is referred to as pharmacogenomics. By understanding the relationship between genetic variants and drug efficacy or toxicity, we are able to optimize pharmacological therapy according to an individual's genotype. Pharmacogenomics research has historically suffered from bias and underrepresentation of people from certain ancestry groups and of the female sex. These biases can arise from factors such as drugs and indications studied, selection of study participants, and methods used to collect and analyze data. To examine the representation of biogeographical populations in pharmacogenomic data sets, we describe individuals involved in gene-drug response studies from PharmGKB, a leading repository of drug-gene annotations, and showcaseCYP2D6, a gene that metabolizes approximately 25% of all prescribed drugs. We also show how the historical underrepresentation of females in clinical trials has led to significantly more adverse drug reactions in females than in males | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a alleles | |
| 650 | 4 | |a biogeographical regions | |
| 650 | 4 | |a diversity genomics | |
| 650 | 4 | |a haplotypes | |
| 650 | 4 | |a pharmacogenomics | |
| 650 | 4 | |a underrepresented populations | |
| 700 | 1 | |a Siddiqui, Moneeza K |e verfasserin |4 aut | |
| 700 | 1 | |a Soremekun, Opeyemi |e verfasserin |4 aut | |
| 700 | 1 | |a Mathur, Rohini |e verfasserin |4 aut | |
| 700 | 1 | |a Gill, Dipender |e verfasserin |4 aut | |
| 700 | 1 | |a Fatumo, Segun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annual review of pharmacology and toxicology |d 1993 |g 64(2024) vom: 23. Jan., Seite 53-64 |w (DE-627)NLM000078379 |x 1545-4304 |7 nnns |
| 773 | 1 | 8 | |g volume:64 |g year:2024 |g day:23 |g month:01 |g pages:53-64 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1146/annurev-pharmtox-030823-111731 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 64 |j 2024 |b 23 |c 01 |h 53-64 | ||